Cardiovascular outcomes in the outpatient kidney transplant clinic: The Framingham risk score revisited

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 3, 2008, Pages 822-828

  Kiberd, Bryce ^a,b   Panek, Romuald ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; AGE; AGED; ARTICLE; DIABETES MELLITUS; DISEASE FREE SURVIVAL; FEMALE; HEALTH SURVEY; HEART DISEASE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; OUTPATIENT DEPARTMENT; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICS; STROKE; TIME;

ADULT; AGE FACTORS; AGED; AMBULATORY CARE FACILITIES; CARDIOVASCULAR AGENTS; CYCLOSPORINE; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS INDICATORS; HEART DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TACROLIMUS; TIME FACTORS;

EID: 44649087813     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00030108     Document Type: Article

References (36)

1. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK: Long-term survival in renal transplant recipients with graft function. Kidney Int 57: 307-313, 2000
2. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7: 158-165, 1996
3. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735-1743, 2000
4. Ducloux D, Kazory A, Chalopin JM: Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 66: 441-447, 2004
5. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ: The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 50: 217-224, 2007
6. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
7. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE study. J Am Soc Nephrol 13: 1918-1927, 2002
8. Roberts MA, Hare DL, Ratnaike S, Ierino FL: Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48: 341-360, 2006
9. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355: 2631-2639, 2006
10. Wilson PW, Nam BH, Pencina M, D'Agostino RB Sr, Benjamin EJ, O'Donnell CJ: C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 165: 2473-2478 2005
11. May A, Wang TJ: Evaluating the role of biomarkers for cardiovascular risk prediction: Focus on CRP, BNP and urinary microalbumin, Expert Rev Mol Diagn 7: 793-804, 2007
12. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: The atherosclerosis risk in communities study. Arch Intern Med 166: 1368-1373, 2006
13. Kiberd B, Keough-Ryan T, Panek R: Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 3: 1393-1399, 2003
14. Bostom AD, Brown RS Jr, Chavers BM, Coffman TM, Cosio FG, Culver K, Curtis JJ, Danovitch GM, Everson GT, First MR, Garvey C, Grimm R, Hertz MI, Hricik DE, Hunsicker LG, Ibrahim H, Kasiske BL, Kennedy M, Klag M, Knatterud ME, Kobashigawa J, Lake JR, Light JA, Matas AJ, McDiarmid SV, Miller LW, Payne WD, Rosenson R, Sutherland DE, Tejani A, Textor S, Valantine HA, Wiesner RH: Prevention of post-transplant cardiovascular disease: Report and recommendations of an ad hoc group. Am J Transplant 2: 491-500, 2002
15. Yusuf S: Two decades of progress in preventing vascular disease. Lancet 360: 2-3, 2002
16. Opelz G, Döhler B: Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 5: 2725-2731, 2005
17. Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, O'Shaughnessy EA, Dahl DC, Silkensen JR, Sahadevan M, Snyder JJ: Hypertension after kidney transplantation. Am J Kidney Dis 43: 1071-1081, 2004
18. Hingorani AD, Vallance P: A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 318: 101-105, 1999
19. Brindle P, Beswick A, Fahey T, Ebrahim S: Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: A systematic review. Heart 92: 1752-1759, 2006
20. Holdas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG: Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 5:2929-2936, 2005
21. Knoll GA, Cantarovitch M, Cole E, Gill J, Gourishankar S, Holland D, Kiberd B, Muirhead N, Prasad R, Tibbles LA, Treleaven D, Fergusson D: The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design. Nephrol Dial Transplant 23: 354-358, 2008
22. Collaborative Group of the Primary Prevention Project. Low dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice. Lancet 357: 89-95, 2001
23. Antiplatelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment BMJ 296: 320-331, 1988
24. Freemantle N, Cleland J, Young P, Mason J, Harrison J: Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 318: 1730-1737, 1999
25. Welten GM, Chonchol M, Hoeks SE, Schouten O, Bax JJ, Dunkelgrün M, van Gestel YR, Feringa HH, van Domburg RT, Poldermans D: Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. Kidney Int 72: 1527-1534, 2007
26. Kiberd J, Panek R, Kiberd B: Strategies to reduce clinical inertia in hypertensive kidney transplant recipients. BMC Nephrol 8: 10, 2007
27. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 47:345-351, 2006
28. Kiberd B, Keough-Ryan T, Kiberd M, Panek R: Cardiovascular risk reduction in the transplant clinic: Running harder to stay in the same place [Abstract]. J Am Soc Nephrol 15: 878A, 2004
29. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM: Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors after a first cardiovascular event: A retrospective cohort study. Can J Cardiol 21: 485-488, 2005
30. Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M: European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2-year follow-up results. Nephrol Dial Transplant 20: 968-973, 2005
31. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Moons P, Borm G, Hilbrands LB: Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 4: 937-945, 2004
32. Waid T: CRAF Study Group. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 19: 573-580, 2005
33. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 13: 1084-1090, 2002
34. Fellstrom BC, Holdas H, Jardine A, Holme I: Cardiovascular risk calculator in renal transplantation [Abstract]. J Am Soc Nephrol 18: 434, 2007
35. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B: Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 4: 1662-1668, 2004
36. Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann EH, Wiecek A, Russ GR, Martinek A, Nonnast-Daniel B; DIRECT Study Group. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. Transplant Proc 37: 1001-1004, 2005